

Hutchinson Institute for Cancer Outcomes Research

# 2024 Annual Report

10 YEARS OF IMPROVING CANCER CARE OUTCOMES



 Fred Hutch Cancer Center



Fred Hutch  
Cancer Center



## Land Acknowledgement

Fred Hutch Cancer Center acknowledges the Coast Salish peoples of this land, the land which touches the shared waters of all tribes and bands within the Suquamish, Tulalip and Muckleshoot nations.

## HICOR Research Portfolio



### Financial Burden of Cancer

Understanding the causes and finding ways to prevent patients and caregivers from experiencing financial hardship.



### Cost Effectiveness

Evaluating and comparing the costs and health outcomes of interventions to inform clinical practice and policy.



### Cancer Screening

Developing methods to improve cancer screening rates and testing interventions to remove barriers in underserved populations.



### Health Disparities

Identifying and addressing preventable differences in the burden of disease between population groups.



### Cancer Care Delivery

Researching how the way care is provided impacts the health outcomes and well-being of patients and survivors.



### Simulation Modeling

Developing computer models to estimate the population-level effects of a new health policy or treatment guideline.

# From the Directors



**Scott Ramsey, MD, PhD**  
Director

In 2024, we celebrated HICOR's 10th anniversary. We take great pride in the impact HICOR has made over the years—fostering a community that leverages our performance measures to drive meaningful improvements in clinical care, launching innovative trials aimed at reducing the financial burden on patients and families, and expanding access to cancer screening and prevention opportunities.

Community has always been at the heart of our mission, and now, more than ever, it is vital to reaffirm our commitment to ensuring that all Washington patients and communities have access to cancer prevention, treatment, and survivorship services. In this report, we share implementation research focusing on making HPV vaccines more easily accessible. We also spotlight our emerging initiative to expand opportunities for cancer research participation in communities throughout Washington state. These efforts are central to our goal of eliminating disparities in cancer outcomes.



**Veena Shankaran, MD, MS**  
Co-Director

It has been our privilege to support trainees dedicated to building portfolios in outcomes research. Over the past decade, fourteen trainees have participated in our program. This year, we were delighted to welcome two new faculty members—Drs. C. Natasha Kwendakwema and Lauren Shih—both medical oncologists and alumni of HICOR's outcomes research training program.

As we reflect on the past ten years, we are grateful for the many supporters and partners who have made HICOR's work possible. We deeply value your continued collaboration as we work together to improve the quality and cost of cancer care for all communities.


A handwritten signature in black ink, appearing to read 'S Ramsey'.

**Scott Ramsey, MD, PhD**

A handwritten signature in black ink, appearing to read 'V Shankaran'.

**Veena Shankaran, MD, MS**

# Faculty Profiles



**Aasthaa Bansal,  
PhD**  
abansal@uw.edu

**Joint Associate Professor,** Public Health Sciences Division, Fred Hutch

**Associate Professor,** School of Pharmacy, UW



**Hiba Khan,  
MD, MPH**  
hkhan@fredhutch.org

**Assistant Professor,** Clinical Research Division, Fred Hutch

**Assistant Professor,** Division of Hematology and Oncology, UW



**Carolyn Rutter,  
PhD**  
crutter@fredhutch.org

**Professor,** Public Health Sciences Division, Fred Hutch



**Mengyang Di,  
MD, PhD**  
mydi@fredhutch.org


**Assistant Professor,** Division of Hematology and Oncology, UW



**C. Natasha  
Kwendakwema,  
MD**  
chipokwe@uw.edu

**Acting Assistant Professor,** Clinical Research Division, Fred Hutch

**Acting Assistant Professor,** Division of Hematology and Oncology, UW



**Parth Shah,  
PharmD, PhD**  
pshah@fredhutch.org

**Assistant Professor,** Public Health Sciences Division, Fred Hutch


**Affiliate Assistant Professor,** School of Public Health, Department of Pharmacy, UW



**Erin Gillespie,  
MD, MPH**  
eringill@uw.edu

**Joint Associate Professor,** Radiation Oncology Division, Fred Hutch

**Associate Professor,** Department of Radiation Oncology, UW



**Christoph Lee,  
MD, MS**  
stophlee@uw.edu

**Professor,** Department of Radiology, UW

**Adjunct Professor,** Health Systems and Population Health, School of Public Health, UW

**Director,** Northwest Screening and Cancer Outcomes Research Enterprise (NW-SCORE), UW



**Lauren Shih,  
MD**  
laurensh@uw.edu

**Assistant Professor,** Clinical Research Division, Fred Hutch

**Assistant Professor,** Division on Hematology and Oncology, UW



**Rachel Issaka,  
MD, MS**  
rissaka@fredhutch.org

**Associate Professor,** Public Health Sciences Division; Clinical Research Division, Fred Hutch

**Associate Professor,** Department of Internal Medicine, Division of Gastroenterology, UW

**Director,** Population Health Colorectal Cancer Screening Program, Fred Hutch and UW Medicine

**Kathryn Surace-Smith Endowed Chair in Health Equity Research,** Fred Hutch



**Janie M. Lee,  
MD, MSc**  
jmlee58@fredhutch.org

**Director of Breast Imaging,** Fred Hutch

**Section Chief,** Breast Imaging, UW

**Professor,** Department of Radiology, UW



**Chris Su,  
MD, MPH**  
chrissu@uw.edu

**Assistant Professor,** Clinical Research Division, Fred Hutch

**Assistant Professor,** Division on Hematology and Oncology, UW



# Transforming Ideas into Action: The HICOR Research Team

Star Trek fans will undoubtedly recognize Captain Picard's famous command, "Make it so," a phrase that epitomizes decisive leadership and action. This could easily serve as the motto for HICOR's research team, whose work involves translating HICOR research from the pages of protocols and grant proposals to the field where discoveries take place.

Led by Karma Kreizenbeck, HICOR's Director of Research and Partnerships, these talented professionals guide studies from launch to completion while ensuring the research is compliant and of the highest quality.

“The HICOR research staff are essential to my work. I trust them to keep projects moving forward, giving me more time to focus on research. With their support, I can move fast and together we keep the work fun.”

— Dr. Carolyn Rutter, Professor,  
Public Health Sciences, Fred Hutch



“Each day, I am in awe of the depth of knowledge and unwavering dedication within our team. Research is full of unexpected twists, and they tackle every challenge with resilience, ingenuity, and a spirit of collaboration. It is an honor and a privilege to lead this exceptional team.”

— Karma Kreizenbeck,  
Director of Research and Partnerships

**Left to right:** Michelle Ndugulile, Program Assistant; Kate Watabayashi, Senior Program Manager, Research and Strategic Initiatives; Long Nguyen, Administrative Coordinator; Talor Hopkins, Project Manager; Morgan Glascock, Project Manager; Karma Kreizenbeck, Director of Research and Partnerships; Ari Bell-Brown, Collaborative Science Manager; Jessie Schwartz, Mixed Methods Data Analyst. **Not pictured:** Nahom Daniel, Project Coordinator. *Photo by Robert Hood.*


# Partnering for Impact

## Expanding Community-Centered Research


Participation in clinical trials improves care and outcomes for cancer patients and reduces care costs. Despite this, less than 5% of cancer patients in Washington state join clinical trials. Barriers to patient participation include a lack of available studies and concerns about time and financial burden. For community oncology clinics, administrative and financial concerns are paramount, followed by study applicability to their practice and patients.

HICOR is working to expand access to cancer clinical trials in Washington by deploying new and sustainable strategies to engage diverse communities in cancer research. These include shifting the clinical trial paradigm beyond industry-sponsored treatment trials to include cancer care delivery studies, which are often easier for patients to join, and partnering with oncology clinics to design studies that address their clinical concerns while minimizing staff burden.

**Research Priorities Identified by Healthcare Providers in Washington State**



### How it Works: Expanding Access to Cancer Clinical Trials in Washington State





114

## New Pilot Studies led by Fred Hutch Investigators in 2024



Principal Investigator:  
**Scott Ramsey, MD, PhD**



Principal Investigator:  
**Veena Shankaran, MD, MS**




Principal Investigator:  
**Erin Gillespie, MD, MPH**



Principal Investigator:  
**Megan Shen, PhD**



Principal Investigator:  
**Hiba Khan, MD, MPH**



— Dr. Erin Gillespie,  
Associate Professor, Division  
of Radiation Oncology,  
University of Washington  
School of Medicine; Primary  
Investigator of PRO-ACTIVE, a  
1-year study funded by a 2024  
Trials Expansion Pilot Award

## Boosting HPV Vaccination in Pharmacies

Pharmacies are among the most accessible healthcare settings in the United States and have the potential to significantly increase human papillomavirus (HPV) vaccination rates, which currently fall well below the national goal of 80% coverage. Despite their convenience for patients, pharmacies remain underused in delivering this critical cervical cancer prevention vaccine.

From 2021 to 2024, our research team conducted two pilot studies aimed at improving HPV vaccine delivery in pharmacies. The results were encouraging—interventions significantly improved pharmacy staff's recommendation strength, confidence in their impact, and proactive engagement in HPV vaccination, supporting clear vaccine recommendations at guideline-aligned ages.


Building on these promising findings, we will launch a more comprehensive study in 2025 to refine and scale these approaches in community pharmacies. Our goal is to make it easier for people to receive the vaccine, while reducing inequities in HPV vaccination rates and health outcomes.



“Every missed vaccination is a missed opportunity to prevent cancer. Pharmacies have the reach, community trust, and resources to help close vaccination gaps.”

— Dr. Parth Shah,  
Principal Investigator

### HPV Vaccination Pilot Studies



#### Empowering pharmacy staff:

Training pharmacy staff in evidence-based communication techniques boosted their confidence in talking to parents about HPV vaccination and strengthened vaccine recommendations.

#### Increasing workflow efficiency and proactivity:

Integrating tailored clinical decision support systems into pharmacy workflows enabled staff to identify eligible patients more easily and make timely vaccination recommendations. This approach streamlined the process and ensured that HPV vaccination became a routine part of care.





## Celebrating 10 Years

In 2014, seventy-five regional leaders from public and private insurance, healthcare policy, research, patient advocacy, and oncology care gathered at the inaugural Value in Cancer Care Summit to identify measurable, actionable priorities for improving cancer care.

HICOR soon created a linked database of healthcare claims, cancer registries, and cost, which today includes data from nearly 500,000 patients. In 2018, HICOR released the first publicly accessible statewide report showing clinic-level quality measures linked to cost in cancer care: **The Community Cancer Care Report**. This report, published annually, guides clinical quality improvement programs throughout Washington state.


**Top:** HICOR's 10th Anniversary celebration (2024)  
*Photos by Robert Hood.*



HICOR Co-Directors Veena Shankaran, MD, MS, and Scott Ramsey, MD, PhD.

HICOR's impact has grown significantly with leadership in the SWOG Cancer Care Delivery Research Committee, the initiation of several national trials addressing financial hardship, an expanding research portfolio driven by a growing faculty team, and a robust trainee program. We are excited to embrace the next decade of growth and innovation.

**Turn the page for more highlights  
from HICOR's first decade!**







**Clockwise from top left:** Preparing posters for the Value in Cancer Care Summit (2015), Celebrating Karma Kreizenbeck's Margaret T. Farwell Outstanding Staff Career Contributions Award (2018), HICOR's 10th Anniversary celebration (2024), Value in Cancer Care data (2016), Participants at the first Value in Cancer Care Summit (2014), HICOR Faculty (2024), Fred Hutch Obliteride (2024), Seattle Indian Health Board's Spirit Walk & Warrior Run (2023), Publishing the first HICOR Annual Report (2015), HICOR Faculty Retreat (2024).



# Honoring the Life and Legacy of Bridgette Hempstead

HICOR mourns the loss of Cierra Sisters founder and longtime research partner, Bridgette Hempstead. Since receiving her own diagnosis nearly three decades ago, Bridgette tirelessly advocated for Black cancer patients. Bridgette's dedication to ending bias in cancer treatment, research, and outcomes has touched many lives and continues to inspire our community.



Read more  
about Bridgette's  
influential legacy

**Clockwise from top:** Bridgette at HICOR's Value in Cancer Care (VCC) Patient Partner meeting (2017); Presenting at Fred Hutch Health Disparities Symposium (2017); With Dr. Rachel Issaka at HICOR's VCC Summit (2018); With Karma Kreizenbeck and Dr. Scott Ramsey at a Cierra Sisters fundraiser (2014); With Drs. Vida Henderson and Veena Shankaran at the Anti-Racism in Oncology video project premiere event (2023); Cierra Sisters' World Cancer Day event (2024).



# Value in Cancer Care Summit



## Improving patient access to care

In 2024, the VCC Summit celebrated a decade of sharing data and facilitating crucial collaborations between providers, payers, researchers and patients. This year's Summit welcomed nearly 200 attendees; the collaborative energy and optimism was palpable. Speakers highlighted the powerful impact of patient advocacy, outlined strategies to reduce financial hardship and address food insecurity for cancer patients, and emphasized the importance of understanding the historical and cultural context of a place and its inhabitants to provide the highest quality medical care. The day concluded with an insightful presentation on the promise and potential pitfalls of multi-cancer detection tests - a new horizon in cancer screening.

**Top left:** Ruth Etzioni, PhD, speaks about multi-cancer detection tests. **Top right:** Marty Chakoian, prostate cancer patient and advocate, speaks as a panelist on expanding access to supportive care.

**Bottom right:** Paula Chambers Raney, a colorectal cancer survivor and patient advocate from Houston, spoke of her delayed diagnosis and the bias she experienced as a gay Black woman navigating her cancer care journey. *Photos by Robert Hood.*

“When I went to Washington, D.C. and shared my story with senators and congresspeople, it changed my life. Advocacy empowered me to make sure what happened to me didn't happen to anyone else.”

— Paula Chambers Raney, Colorectal Cancer Survivor and Patient Advocate





Pancreas cancer survivor Miggie Olsson describes her cancer experience.

**Right:** Dr. Banu Symington, who practices medicine at a county hospital in Rock Springs, Wyoming, shared how the facts of rural life - such as poor internet access, food deserts, and transportation challenges - lead to inferior health outcomes. She called for improvements in telehealth licensure and reimbursement and the decentralization of clinical trials to help reduce rural health disparities.

“Inferior health outcomes can be attributed to lack of access to screening, lack of providers, lifestyle factors such as smoking and decreased health and tech literacy. But that’s only part of the picture.”

— Banu Symington, MD, Sweetwater County Hospital



## Community Cancer Care Report

Drs. Veena Shankaran and Scott Ramsey presented an overview of the 2024 Community Cancer Care Quality and Cost report, highlighting new state-level metrics around biomarker and germline testing. HICOR’s community reporting aims to examine regional trends in cancer care delivery and identify opportunities for improving cancer care.



**Read the 2024  
Community Cancer  
Care Report**

“We all want the same thing for cancer patients - best possible outcomes, highest quality care, and reasonable cost. The Community Cancer Care Report helps us develop quality improvement strategies to get there.”

— Perry Soriano, MD, Providence Surgical Oncology



## A Year In Conferences

### American Society of Clinical Oncology Annual Meeting

Chicago, IL

■ **Lauren Shih**, "End of life care in head and neck squamous cell carcinoma compared to other solid tumors in Washington State"

■ **Chris Su**, "Association between financial fragility and treatment patterns in multiple myeloma"

■ **Hiba Khan**, "Germline Gene-Specific Associations in a Large Prostate Cancer Cohort"

### Digestive Disease Week

Washington, DC

■ **Ari Bell-Brown**, "The Association Between Letter Type and Fecal Immunochemical Test Completion in a Population Health Outreach Program"

■ **Rachel Issaka**, State of the Art Presentation: "Payer Reform and Health Advocacy in Endoscopy"

### National Academies' Workshop: Opportunities and Challenges for the Development and Adoption of Multicancer Detection Tests

Washington, DC

■ **Rachel Issaka**, "Health Equity Considerations for Multi-Cancer Detection (MCD) Tests: Context, Trials & Communications"

■ **Scott Ramsey**, "MCD Testing in the United States Estimating Cost-Effectiveness and Budget Impact"

### Society for Implementation Research Collaboration Conference

Denver, CO

■ **Morgan Glascock** (authored by **Jessie Schwartz**), "Nudging HPV vaccination rates: Partnering with software developers and pharmacies to improve vaccine clinical decision support systems"

# Leading the Conversation


This year, HICOR presented 12 posters and talks at academic conferences spanning topics from efforts to evaluate emerging cancer screening technologies to the association between patient financial fragility and the treatments they receive.



### North American Primary Care Research Group Annual Meeting

**Ari Bell-Brown**, "Engaging Practice-Based Research Networks, Primary Care, and the Community in the National Cancer Screening Research Network"

Québec City, Canada



### American Society of Hematology Annual Meeting

**Chris Su**, "Associations of Long-Term Financial Hardship with Autologous Transplant and Overall Survival in Patients with Multiple Myeloma"

San Diego, CA



### American College of Gastroenterology Annual Meeting

**Talor Hopkins**, "Decreasing Patient Fear of Colonoscopy After an Abnormal Fecal Immunochemical Test: Results from a Pilot Video Decision Aid"

Philadelphia, PA



### Digestive Disease Week

**C. Natasha Kwendakwema**, "Colorectal Cancer Screening and Surveillance: Clinical Studies to Improve Uptake, Increase Adherence & Address Racial Disparities"

Washington, DC



# Select Publications

- **Simpson S, Yu K, Bell-Brown A, Kimura A, Meisner A, Issaka RB.** Factors Associated With Mailed Fecal Immunochemical Test Completion in an Integrated Academic-Community Healthcare System. *Clin Transl Gastroenterol.* 2024 Oct 1;15(10):e1.
- **Kwendakwema CN, Hopkins T, Bell-Brown A, Simianu VV, Shankaran V, Issaka RB.** Clinician perceptions on barriers and facilitators to 1-year surveillance colonoscopy completion in survivors of colorectal cancer. *Cancer Med.* 2024; 13:e70244.
- **Verdini NP, Bryl KL, Baser RE, Lapen K, Mao JJ, Gillespie EF.** Patient-Reported Outcomes as a Recruitment Strategy for Clinical Trial Enrollment. *JAMA Oncol.* 2024 Jun 1;10(6):784-788.
- **Khan HM.** Editorial Commentary on "Racial Disparities in Diagnosis and Treatment of Depression Associated with Androgen Deprivation Therapy for Prostate Cancer". *Urology.* 2024 Apr;186:81.
- **Saber W, Bansal A, Li L, Scott BL, Sangaralingham LR, Thao V, Roth JA, Wright W, Steuten LMG, Pidala JA, Mishra A, Maziarz RT, Westervelt P, McGuirk JP, Cutler C, Nakamura R, Ramsey SD.** Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102. *JCO Oncol Pract.* 2024 Apr;20(4):572-580.
- **Chung DC, Gray DM 2nd, Singh H, Issaka RB, Raymond VM, Eagle C, Hu S, Chudova DI, Talasaz A, Greenson JK, Sinicrope FA, Gupta S, Grady WM.** A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening. *N Engl J Med.* 2024 Mar 14;390(11):973-983.
- **Waters AR, Meehan K, Atkins DL, Ittes AH, Ferrari RM, Rohweder CL, Wangen M, Ceballos RM, Issaka RB, Reuland DS, Wheeler SB, Brenner AT, Shah PD.** How pharmacists would design and implement a community pharmacy-based colorectal cancer screening program. *Prev Oncol Epidemiol.* 2024;2(1):10.1080/28322134.2024.2332264.
- **Issaka RB, Ibekwe LN, Todd KW, Burnett-Hartman AN, Clark CR, Del Vecchio NJ, Kamineni A, Neslund-Dudas C, Chubak J, Corley DA, Haas JS, Honda SA, Li CI, Winer RL, Pruitt SL.** Association between racial residential segregation and screening uptake for colorectal and cervical cancer among Black and White patients in five US health care systems. *Cancer.* 2024 Dec 15;130(24):4287-4297.
- **Kimura A, Bell-Brown A, Akinsoto N, Wood J, Peck A, Fang V, Issaka RB.** Implementing an Organized Colorectal Cancer Screening Program: Lessons Learned From an Academic-Community Practice. *AJPM Focus.* 2024 Jan 7;3(2):100188.
- **Di M, Su CT, Cowan AJ, Gopal AK, Banerjee R.** Mitigating time toxicity in lymphoma and multiple myeloma. *Leuk Lymphoma.* 2024 Oct;65(10):1418-1429.
- **Su CT, Shankaran V.** Digital symptom assessment tools: the next frontier in financial toxicity screening. *Nat Rev Clin Oncol.* 2024 Feb;21(2):85-86.
- **Gillespie EF, Santos PMG, Curry M, Salz T, Chakraborty N, Caron M, Fuchs HE, Ledesma Vicioso N, Mathis N, Kumar R, O'Brien C, Patel S, Guttmann DM, Ostroff JS, Salner AL, Panoff JE, McIntosh AF, Pfister DG, Vaynrub M, Yang JT, Lipitz-Snyderman A.** Implementation Strategies to Promote Short-Course Radiation for Bone Metastases. *JAMA Netw Open.* 2024 May 1;7(5):e2411717.
- **Nascimento de Lima P, van den Puttelaar R, Knudsen AB, Hahn AI, Kuntz KM, Ozik J, Collier N, Alarid-Escudero F, Zaubler AG, Inadomi JM, Lansdorp-Vogelaar I, Rutter CM.** Characteristics of a cost-effective blood test for colorectal cancer screening. *J Natl Cancer Inst.* 2024 Oct 1;116(10):1612-1620.
- **Bell-Brown A, Hopkins T, Watabayashi K, Overstreet K, Leahy A, Bradshaw E, Gallagher K, Obenchain J, Padron A, Scott B, Flores B, Shankaran V.** A proactive financial navigation intervention in patients with newly diagnosed gastric and gastroesophageal junction adenocarcinoma. *Support Care Cancer.* 2024 Feb 24;32(3):189.
- **Ramsey SD, Onar-Thomas A, Wheeler SB.** Real-World Database Studies in Oncology: A Call for Standards. *J Clin Oncol.* 2024 Mar 20;42(9):977-980.
- **Jones SM, Yi J, Henrikson NB, Panattoni L, Shankaran V.** Financial hardship after cancer: revision of a conceptual model and development of patient-reported outcome measures. *Future Sci OA.* 2024 May 14;10(1):FSO983.
- **Odebunmi OO, Wangen M, Waters AR, Ferrari RM, Marciniak MW, Rohweder C, Wheeler SB, Brenner AT, Shah PD.** Colorectal cancer screening knowledge among community pharmacists: A national survey. *J Am Pharm Assoc (2003).* 2024 May 23;102130.
- **Warren JL, Mariotto AB, Stevens J, Davidoff AJ, Shankaran V, Ward KC, Wu XC, Schwartz SM, Penberthy L, Yabroff KR.** Association of Major Adverse Financial Events and Later-Stage Cancer Diagnosis in the United States. *J Clin Oncol.* 2024 Mar 20;42(9):1001-1010.
- **Coronado GD, Bienen L, Burnett-Hartman A, Lee JK, Rutter CM.** Maximizing scarce colonoscopy resources: the crucial role of Stool-Based tests. *J Natl Cancer Inst.* 2024 Feb 4:djae022.

# HICOR External Advisory Board


**Alan J. Balch, PhD**

Chief Executive Officer, Patient Advocate Foundation and National Patient Advocate Foundation


**Ya-Chen Tina Shih, PhD**

Professor, Departments of Radiation Oncology and Medicine, University of California, Los Angeles

Director, Cancer Health Economics Research Program, Jonsson Comprehensive Cancer Center


**Ethan Basch, MD, MSc**

Richard M. Goldberg Distinguished Professor and Chief of Oncology

Physician-in-Chief, Linenberger Comprehensive Cancer Center, University of North Carolina

Director of Cancer Outcomes Research, University of North Carolina


**Jennifer Temel, MD**

Professor of Medicine, Harvard Medical School

Clinical Director Thoracic Oncology, Massachusetts General Hospital

Co-Director, Cancer Outcomes Research and Education, Massachusetts General Hospital


**Diana Brixner, PhD, RPh**

Chair, HICOR External Advisory Board

Professor, Department of Pharmacotherapy, University of Utah

Executive Director, Pharmacotherapy Outcomes Research Center, University of Utah

Director of Outcomes, Program in Personalized Health Care, University of Utah


**Stephanie B. Wheeler, PhD, MPH**

Michael S. O'Malley Endowed Professor, Department of Health Policy & Management, Gillings School of Global Public Health

Associate Director of Community Outreach and Engagement, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill


**Maria Lopes, MD, MS**

Chief Medical Officer, CDMI/Magellan Health


**Peter Yu, MD**

Physician-in-Chief, Hartford HealthCare Cancer Institute

Clinical Member, Memorial Sloan Kettering Cancer Center


**Raymond Osarogiagbon, MD, FACP**

Chief Scientist, Baptist Memorial Health Care

Director, Multidisciplinary Thoracic Oncology Program and Thoracic Oncology Research Group, Baptist Cancer Center

# Hutchinson Institute for Cancer Outcomes Research



## Our Team

**Back left to right:** Sarah Miller, Qin Sun, Kaiyue Yu, Talor Hopkins, Morgan Glascock, Karma Kreizenbeck, Scott Ramsey, Winona Wright, Rachel Issaka, Long Nguyen, Shannon Kestner, Lauren Shih, C. Natasha Kwendakwema

**Front left to right:** Nahomi Guzman, Michelle Ndugulile, Lily Li, Kristy Drury, Kate Watabayashi, Ari Bell-Brown, Judy Nelson, Carolyn Rutter, Veena Shankaran, Catherine Fedorenko, Jessie Schwartz, Amanda Kimura, Kaitie Todd, Hiba Khan

**Not Pictured:** Parth Shah, Chris Maerzluft, Angie Madrid, Nahom Daniel, Chris Su, Christoph Lee, Janie Lee, Mengyang Di





## **Hutchinson Institute for Cancer Outcomes Research**

To learn more, scan the QR code or visit [FredHutch.org/HICOR](https://FredHutch.org/HICOR)